Literature DB >> 6738343

Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis.

M Peters-Golden, R A Wise, P Schneider, M Hochberg, M B Stevens, F Wigley.   

Abstract

The course of functional pulmonary involvement in systemic sclerosis remains controversial; and it is not known if specific clinical or demographic features are predictive of subsequent changes in pulmonary function. To address these questions, we conducted a non-concurrent prospective study of serial pulmonary function in 24 patients with systemic sclerosis unselected for pulmonary involvement over a mean follow-up interval of 59.7 months. Initial values for the entire group demonstrated a mild restrictive defect with a mild reduction in gas exchange. Although a restrictive pattern was most common, normal and obstructed pulmonary function were seen. Mean rates of change of FVC, TLC, FEV1/FVC, and Dco for the entire group were not different from normal, but substantial variability in the course of pulmonary functional involvement was seen among individuals. Changes in gas transfer, lung volumes, and airflow can occur independent of each other. Rates of change in pulmonary function were not predicted by initial pulmonary function, race, sex, duration of disease, cardiac involvement, roentgenographic fibrosis, or regression of skin disease. Patients with severe Raynaud' phenomenon exhibited the greatest fall in Dco over time, suggesting an association between peripheral and pulmonary vascular involvement. A correlation between exertional dyspnea and rapid loss of Dco was noted. Former smokers had significantly greater rates of loss of FVC and Dco than either non-smokers or current smokers, suggesting that cessation of smoking was a response to rapidly declining function in a subgroup of susceptible smokers. We detected a wide spectrum of severity of pulmonary prognosis in systemic sclerosis, ranging from normal pulmonary function to rapidly progressive disease leading to death. This study indicates that patients with prolonged survival do not necessarily have a rapidly progressive pulmonary component, but those with severe Raynaud's phenomenon and susceptible smokers are at very high risk for rapid deterioration of pulmonary function.

Entities:  

Mesh:

Year:  1984        PMID: 6738343     DOI: 10.1097/00005792-198407000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  15 in total

1.  Predictors of end stage lung disease in systemic sclerosis.

Authors:  V Steen
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

Review 2.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Armin Schnabel; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

3.  Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.

Authors:  Aggeliki Rapti; Vasileios Kouranos; Elias Gialafos; Konstantina Aggeli; John Moyssakis; Anastasios Kallianos; Charalampos Kostopoulos; Ourania Anagnostopoulou; Petros P Sfikakis; Athol U Wells; George E Tzelepis
Journal:  Lung       Date:  2012-12-11       Impact factor: 2.584

4.  The prognostic factors of systemic sclerosis for survival among Koreans.

Authors:  Jinhyun Kim; Sue Kyung Park; Ki Won Moon; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980

5.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

6.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

7.  Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.

Authors:  Marie Hudson; Deborah Assayag; Melissa Caron; Benjamin D Fox; Andrew Hirsch; Russell Steele; Rebecca Gaudreau-Taillefer; Solène Tatibouet; Lawrence Rudski; Murray Baron
Journal:  Clin Rheumatol       Date:  2013-06-04       Impact factor: 2.980

8.  Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?

Authors:  M J Abramson; A J Barnett; G O Littlejohn; M M Smith; S Hall
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

9.  Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up.

Authors:  C Agustí; A Xaubet; J Roca; A G Agustí; R Rodriguez-Roisin
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

10.  Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes.

Authors:  Christine Peoples; Thomas A Medsger; Mary Lucas; Bedda L Rosario; Carol A Feghali-Bostwick
Journal:  J Scleroderma Relat Disord       Date:  2016-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.